The new drug MK-0616 works by inhibiting PCSK9 protein, a reduction that helps the liver break down low-density lipoprotein cholesterol.
A recent study examined the effectiveness of MK-0616 as an oral PCSK9 inhibitor. The study included more than 380 people with high LDL cholesterol levels and a history of heart disease or risk factors.
Participants who took any dose of the drug appeared to have a significant reduction in LDL cholesterol levels compared to placebo. The reduction in those receiving the 30 mg dose was over 60%, 18 mg 59%, 12 mg 55%, and 6 mg 41%. Other biomarkers of bad cholesterol also fell. The team did not notice any signs of side effects at any dose.
A more detailed study of the MK-0616 will require further testing.
News cannot be equated with a doctor’s prescription. Consult an expert before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
